抗体偶联药物在尿路上皮癌中的研究进展

Research Progress of Antibody-drug Conjugates Therapy in Urothelial Carcinoma

尿路上皮癌是常见的泌尿系统恶性肿瘤,易复发、转移且临床预后较差,现有治疗方案未能显著提高患者的临床获益。抗体偶联药物是一种通过化学连接子将单克隆抗体与小分子细胞毒性载荷高效偶联的新型抗肿瘤药物,以更加精准化和个体化的诊疗特点在尿路上皮癌的临床研究中取得重要进展。全文重点对近年来抗体偶联药物在尿路上皮癌中的研究进展进行综述。

Urothelial carcinoma is a common malignant tumor of the urinary system, which is prone to recurrence and metastasis and has a comparatively dismal prognosis. The existing treatment regimens failed to significantly improve the clinical benefits of patients with advanced urothelial carcinoma. Antibody-drug conjugate is an innovative antineoplastic drug consisting of a monoclonal antibody effectively conjugated to a small molecular cytotoxic payload via the linker. It makes significant progress in the clinical research of urothelial carcinoma with more precise and individualized treatment characteristics. This article systematically reviews the recent progress of antibody-drug conjugates in urothelial carcinoma.